Recently, AICROS, a leading global CRO consortium, successfully held its 2026 annual meeting in Shanghai. This marks the consortium’s first annual meeting hosted in China since its establishment. Hosted by Asymchem Clinical (Clin-nov), the consortium’s sole Chinese CRO member, the event drew member representatives from over ten countries and regions globally to Shanghai. Participants discussed frontier trends in global clinical research and explored innovative pathways for cross-border collaboration.
Group Photo of Attendees
As a CRO consortium with global reach and influence, AICROS unites high-caliber local CRO institutions to deliver customized clinical services with global coverage and international standards for multinational pharma and biotech companies. The consortium promotes experience sharing and constructive collaboration among members. Leveraging a standardized quality control system, it mitigates risks in cross-border clinical trials and accelerates new drug development.
Equipped with End-to-End clinical service capabilities meeting international standards for innovative drug development, Asymchem Clinical (Clin-nov) was invited to join AICROS in 2024. The team passed rigorous on-site audits and full-system training, officially becoming an AICROS-certified member and the consortium’s sole Chinese CRO member.
The two-day annual meeting centered on core industry themes including the ongoing globalization of innovative drug development, as well as opportunities and challenges in cross-border clinical trials. Participants also discussed consortium governance, project quality control reviews and forward-looking strategic planning.
At the opening session, Qi Yin, Vice President of Asymchem Pharmaceuticals Group and COO & CSO of Asymchem Clinical (Clin-nov), delivered a welcome address. He extended warm greetings to consortium representatives and shared in-depth insights on hot topics: global trends in innovative drug R&D, Chinese innovative drugs going global, and overseas clients actively launching clinical trials in China. He hoped the conference would foster consensus and expand the scope of the consortium’s international collaboration.
Qi Yin
Vice President of Asymchem Pharmaceuticals Group, COO & CSO of Asymchem Clinical (Clin-nov)
Subsequently, Andreas Beust, Chairman of the AICROS Consortium, delivered remarks. He spoke highly of service efficiency and quality compliance in prior global clinical trial collaborations with Asymchem Clinical (Clin-nov), and voiced strong anticipation for deeper cooperation going forward.
Andreas Beust
Chairman of the AICROS Consortium
During the meeting, all members presented updates on their companies’ operations and project delivery over the past year. New members introduced their corporate profiles and service portfolios. The consortium also held elections for its new board of directors. Member institutions collectively reviewed outcomes of annual collaborative projects, consolidated audit and inspection findings, and shared cross-border collaboration experience.
In addition, representatives jointly discussed the consortium’s future development roadmap and exchanged cooperation models covering global multi-center clinical trial collaboration, cross-border regulatory compliance, Chinese innovative drugs going global, and overseas new drugs entering China for clinical trials. Participants explored opportunities for resource connectivity and project synergy across multinational CROs.
On-site Exchange Between Consortium Member Representatives
Hosting the AICROS annual meeting for the first time in Shanghai marks an important milestone for the consortium to deepen its footprint in the Asia-Pacific market and refine its global strategic layout. It also highlights China’s pivotal role in international CRO exchanges. Moving forward, Asymchem Clinical (Clin-nov) will continue to capitalize on its strengths as an AICROS member, expand international collaboration via this global platform, and facilitate efficient, coordinated development of global clinical research.
